First Page | Meta Content | |
---|---|---|
![]() | Document Date: 2014-11-06 23:49:33Open Document File Size: 685,05 KBShare Result on FacebookCompanyRoche Diagnostics Australia Pty Limited / Roche Diagnostic Australia Pty Limited / Roche Products Pty Limited / BRAF / Roche Diagnostics Pty Ltd / PBAC / MSAC / /CurrencyUSD / /EventProduct Issues / FDA Phase / /FacilityAuthority (NATA)/Royal College of Pathologists / /IndustryTermhealth services / clinical management / treatment of melanoma / agreed clinical protocols / health technology assessments / /MedicalConditionBRAF V600E-mutated melanomas / metastasis / BRAF non-V600E Mutation Positive Disease / thrombocytopenia / sun-exposed melanoma / cutaneous metastatic melanomas / melanoma / metastatic non-small cell lung cancer / IV cutaneous melanoma / breast cancer / IV (metastatic) melanoma / IV metastatic cutaneous melanoma / IV metastatic melanoma / progressive disease / IV melanoma / tumour / Australian melanoma / BRAF V600 positive melanoma / cutaneous cutaneous squamous cell carcinoma / tumours / metastatic melanoma / /MedicalTreatmentchemotherapy / clinical protocols / platelet transfusion / /OrganizationNational Association / World Health Organization / Therapeutic Goods Administration / Medicare / College of Pathologists of Australasia / Pathology Services Advisory Committee / Department of Health / Australian Health Ministers’ Advisory Council / /PositionMinister / consultant physician / Governor / pathologist / Executive / /ProductV600E / dacarbazine / amount / V600 / /Technologydiagnostic tests / agreed clinical protocols / chemotherapy / /URLwww.msac.gov.au / /SocialTag |